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Objectives. We sought to evaluate the effects of intermittent
transdermal nitroglycerin (TD-NTG) on the occurrence of ischemia
during patch-off hours in patients with stable angina pectoris receiv-
ing a beta-adrenergic blocking agent or calcium antagonist, or both.
Background. The current recommendations for the use of
intermittent TD-NTG may be associated with the occurrence of
rebound ischemia.
Methods. This was a multicenter, randomized, double-blind,
placebo-controlled, crossover trial with three study periods. Tol-
erability to TD-NTG was assessed in Period I. Seventy-two pa-
tients were assigned to receive either double-blind transdermal
placebo or maximally tolerated TD-NTG for 2 weeks (Period II)
and were then crossed over to the alternative treatment for
another 2 weeks (Period III). The patients were instructed to
apply medication daily at 8 AM, to remove it at 10 PM and to note
symptoms and sublingual nitroglycerin (SL-NTG) use in a diary.
The occurrence of ischemia was assessed from patient-perceived
angina, symptom-limited exercise treadmill test (ETT) and 48-h
ambulatory electrocardiographic (AECG) monitoring.
Results. Transdermal NTG (0.2 to 0.4 mg/h) significantly
reduced the magnitude of ST segment depression at angina onset
during ETT compared with placebo. Total angina frequency was
not significantly different between TD-NTG (mean [6SD] 3.2 6
4.2) and placebo (3.3 6 5.2). During patch-off hours, angina
frequency increased with TD-NTG (1.1 6 2.1) compared with
placebo (0.7 6 1.6) (p 5 0.03). Similar trends for an increase in
ischemia after TD-NTG were also observed from AECG analyses.
Specifically, ischemia frequency tended to be lower during patch-
off hours for placebo than with TD-NTG (0.05 6 0.09 vs. 0.08 6 0.20
episodes/h, respectively, p 5 0.08), even though frequency of ischemia
tended to be higher during patch-on hours for placebo than with
TD-NTG (0.12 6 0.19 vs. 0.07 6 0.15 episodes/h, respectively, p 5
0.11). During placebo, ischemia frequency decreased 58% (patch-on
to patch-off, p 5 0.01) compared with a 14% increase with TD-NTG.
These changes attenuate the usual circadian variation in ischemia.
Conclusions. An increase in ischemia frequency during patch-
off hours after use of intermittent TD-NTG was perceived by patients,
and this subjective finding was supported by a corresponding
trend for AECG ischemia to increase during these same hours.
(J Am Coll Cardiol 1997;30:955–61)
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Transdermal nitroglycerin (TD-NTG) patches were originally
introduced as a sustained-action NTG delivery system when
pharmacokinetic studies showed that this formulation pro-
duced steady-state blood concentrations when affixed to skin
(1). Notably, investigations of safety and efficacy were not
conducted before approval. Since then, results of a number of
trials revealed that TD-NTG patch use is associated with
development of partial or complete tolerance when applied
continuously over 24 h (2). As a consequence, labeling of
TD-NTG patches was changed to read “. . . in order to avoid
tolerance to NTG drug-free intervals of 10–12 hours are
known to be sufficient; shorter intervals have not been well
studied” (3).
If a TD-NTG patch is used in this manner, it is possible that
patients who have been relatively free of ischemia while
wearing the TD-NTG patch (patch-on) may develop more
ischemia during the 10- to 12-h nitrate-free interval (patch-off).
This possible “rebound ischemia phenomenon” has not been
well studied. Accordingly, this study was designed to evaluate
the effects of intermittent TD-NTG on the frequency of
perceived (i.e., angina) as well as objectively documented
myocardial ischemia (i.e., ST segment depression) and to
determine whether ischemia increases during the patch-off
period in patients with stable angina taking other medications
to suppress angina.
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Methods
Study design. This was a multicenter (see Appendix),
double-blind, placebo-controlled, crossover study that in-
cluded three experimental periods. The first period was the
qualifying and dose tolerability phase, which lasted 3 weeks.
The second and third periods each lasted 2 weeks and com-
prised the double-blind evaluation phase.
In Period I, if a patient was using any nitrate preparation, it
was discontinued gradually, except for sublingual-NTG (SL-
NTG), which was permitted for relief of angina at any time
throughout the study. All other medications were continued
for the study duration at a constant dose if such therapy had
been used in the same dose for at least 4 weeks before
enrollment. After determining qualification and dose tolera-
bility, patients were randomized by a centrally generated code
to receive either active TD-NTG or placebo. In Period II, after
2 weeks of therapy and after assessments for ischemia, patients
were crossed over to alternate treatment. After another 2
weeks in period III, assessments for ischemia were repeated.
The study was approved by the Institutional Review Boards of
all participating centers, and each patient gave written, in-
formed consent before participation.
Study patients. The patients were recruited from 12 cen-
ters and qualified for entry if they had 1) one or more typical
angina episodes during the month before study entry; 2)
evidence of coronary artery disease (CAD) by at least one of
the following criteria: a) previously documented myocardial
infarction; b) concordant abnormalities consistent with CAD
on two different types of stress tests (e.g., electrocardiography
and thallium perfusion); or c) angiographic evidence of $70%
diameter narrowing of one or more major coronary arteries; 3)
evidence of myocardial ischemia during an exercise treadmill
test (ETT); and 4) transient ischemia on ambulatory electro-
cardiographic (AECG) monitoring within 3 weeks before
randomization. Ischemia was considered present when hori-
zontal or downsloping ST segment depression $1 mm from the
level recorded before the episode persisted for either three
consecutive beats during ETT or for $1 min during AECG
monitoring. All AECG readings were evaluated at a core
laboratory by investigators who had no knowledge of the other
findings, and ischemic-type ST segment depression lasting $5
min/48 h or two or more episodes/48 h was required for
qualification.
Exclusion criteria included myocardial infarction, surgical
revascularization or angioplasty within 3 months. Also ex-
cluded were those patients for whom nitrates were contraindi-
cated, those admitted to the hospital for unstable angina within
the previous 4 weeks and those with other medical condition(s)
that would interfere with evaluation or follow-up. Patients with
rest electrocardiographic (ECG) abnormalities likely to inter-
fere with interpretation of ECG changes of ischemia (e.g.,
bundle branch block, paced rhythm, $1.0 mm ST segment
depression, left ventricular hypertrophy) were also excluded.
Patient evaluations. During the first visit in Period I, a
medical history and physical examination were obtained. Each
patient was instructed to record in a diary the number of
perceived angina episodes, activity associated with its onset
and SL-NTG consumption. Each patient completed a
symptom-limited ETT using a modified Bruce protocol and
wore an AECG monitor for 48 h. During ETT, blood pressure
was recorded by a cuff sphygmomanometer and the ECG was
recorded from 12 leads. The AECG monitor was a cassette
type with two bipolar leads whose position had been optimized
to those showing the greatest magnitude of ST segment
depression during ETT.
Period I. During the last week of Period I, dose tolerability
to the active, intermittent TD-NTG patch was assessed. Pa-
tients were instructed to wear the patch for 14 h/day (patch-on
time) and to remove it at bedtime for the next 10 h (patch-off
time). Patients with no history of nitrate sensitivity were first
given a 0.4 mg/h dose of TD-NTG. If no adverse effects were
reported after 3 days, the dose was increased to 0.6 mg/h for
another 3 days. If mild or tolerable adverse effects occurred
with the 0.4 mg/h dose, the higher dose was not evaluated. If
intolerable adverse effects occurred with the 0.4 mg/h dose, it
was decreased to 0.2 mg/h. Patients with a history of nitrate
sensitivity were initially given 0.2 mg/h and titrated upward
accordingly. Patients unable to tolerate 0.2 mg/h failed to
qualify and did not continue in the study. All patients were
asked not to use SL-NTG prophylactically.
Periods II and III. Each patient successfully completing
qualifying procedures was then randomized to receive inter-
mittent therapy with either a double-blinded placebo patch or
an active TD-NTG patch individualized to the best tolerated
dose identified in Period I. As before, patients were instructed
to wear the patch for 14 h/day and to remove it at bedtime for
the next 10 h. At the end of 2 weeks of double-blinded therapy
(Period II), an ETT and 48-h AECG were completed. In
Period III, each patient was crossed over to the alternative
treatment and the same procedures were repeated. During
biweekly clinic visits, patients were questioned about the
occurrence of possible adverse effects and diaries were re-
viewed.
Data analysis and statistical considerations. Response
variables of interest from the angina diaries and AECGs were
frequency of perceived angina and frequency and duration of
AECG-detected ischemia during both patch-on (8 AM to
10 PM) and patch-off (10 PM to 8 AM) hours. Because duration
of patch-on and patch-off periods were different, ischemia was
expressed as the number of episodes or minutes per hour.
From the ETT the following were tabulated: time to onset of
Abbreviations and Acronyms
AECG 5 ambulatory electrocardiogram, electrocardiographic
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
ETT 5 exercise treadmill test
SL-NTG 5 sublingual nitroglycerin
TD-NTG 5 transdermal nitroglycerin
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angina and/or 1-mm ST segment depression, total duration of
ETT, maximal ST segment depression, rate–pressure product
at onset of angina and extent of ST segment depression.
To investigate possible diurnal variation of AECG isch-
emia, frequency and duration of ischemia were determined for
2-h periods throughout the recording session. Data were then
summarized by four time periods: midnight to 6 AM, 6 AM to
noon, noon to 6 PM and 6 PM to midnight.
The limiting variable for sample size calculation was deter-
mined to be a change in total weekly number of AECG-
detected ischemic episodes. Observations from a previous
study using similar patient-entry criteria suggested that an
average of 2 episodes of ischemia per 48 h of AECG monitor-
ing (7/week [range 2 to 14]) could be expected. It was desirable
to be able to detect a reduction of two episodes per week, on
average, from the placebo condition to intermittent TD-NTG.
The standard deviation of differences was estimated to be 5. To
detect a mean difference of 2 with a two-tailed alpha of 0.05 at
a power of 95%, the estimated sample size was 82 patients. The
purpose of this overestimation was to be able to maintain
adequate (e.g., 90%) statistical power if 5% to 10% of re-
cruited patients were unable to complete the study.
Response variables were compared using methods appro-
priate for crossover trials, which included tests for order and
period effects (4). Repeated measures analysis of variance was
performed to evaluate treatment, carryover and period effects.
Nonparametric Wilcoxon rank-sum tests were also used to
evaluate treatment and period effects. The results are summa-
rized as mean value 6 SD and significance was defined at p #
0.05.
Results
A total of 72 patients met all qualifying criteria and
completed all study periods and the pertinent clinical charac-
teristics of these patients are summarized in Table 1. Subjects
were 64 6 8 years old (range 40 to 77), and 93% were men.
Approximately half of the patients had a previous revascular-
ization procedure, 42% had hypertension, 46% had hypercho-
lesterolemia and 51% were taking a calcium antagonist and
46% a beta-blocker, whereas 76% had used SL-NTG before.
Randomization distributed these baseline characteristics so
that there were no significant differences between those who
received a double-blind TD-NTG patch first and those who
received a double-blind placebo patch first. No significant
order or period effects for any variable were observed and no
interaction between TD-NTG and beta-blocker or calcium
antagonist was observed.
Tolerability results. After completion of Period I, the
optimal dose of TD-NTG was 0.2 mg/h, 0.4 mg/h and 0.6 mg/h
in 28%, 29% and 43% of patients, respectively. During dose
tolerability testing, 36% of patients reported no adverse effects
at the maximal dose. The most frequently reported adverse
effects were dizziness (14%) and headache (5%), but no
serious adverse effects occurred. During subsequent double-
blind periods, mild skin irritation and itching were reported by
five patients, one of whom developed mild contact dermatitis.
The frequency of these skin problems was similar with placebo
(n 5 3) and TD-NTG (n 5 2). Headaches were reported by
four patients using active TD-NTG and by one using placebo.
While using placebo, another patient developed prolonged
chest pain necessitating an emergency room visit.
Double-blind period results. Table 2 summarizes the ef-
fects of TD-NTG and placebo on ETT variables in all patients
with complete data. As expected, use of TD-NTG was associ-
ated with a significant decrease in ischemia at the onset of
angina, as reflected by a reduction in the magnitude of ST
segment depression as compared with placebo. Angina diaries
(Table 3) revealed that there was no significant difference in
the total number of perceived angina episodes reported during
Table 1. Clinical Characteristics of 72 Study Patients
Age (yr) 64 6 8
Men 67 (93)
History of
Myocardial infarction 24 (33)
Hypertension 30 (42)
Diabetes mellitus 11 (15)
Hypercholesterolemia 33 (46)
PTCA or CABG 37 (51)
Concomitant therapy
ACE inhibitor 4 (6)
Beta-blocker 33 (46)
Calcium channel blocker 37 (51)
Insulin or oral hypoglycemic drug 7 (10)
Diuretic or other antihypertensive agent 7 (10)
Data are presented as mean value 6 SD or number (%) of patients. ACE 5
angiotensin-converting enzyme; CABG 5 coronary artery bypass graft surgery;
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Exercise Testing Results
Placebo TD-NTG p Value*
At rest
Heart rate (beats/min) 67 6 12 67 6 14 0.86
SBP (mm Hg) 136 6 16 132 6 18 0.08
DBP (mm Hg) 76 6 10 76 6 10 0.79
At onset of 1-mm ST
segment depression
Heart rate (beats/min) 106 6 14 106 6 14 0.74
SBP (mm Hg) 159 6 23 159 6 25 0.96
DBP (mm Hg) 80 6 12 79 6 12 0.55
Rate–pressure product 17,113 6 3,826 17,117 6 4,320 0.99
Time (min) 5.4 6 2.4 5.4 6 2.1 0.93
At onset of moderate angina
Heart rate (beats/min) 109 6 15 107 6 15 0.47
SBP (mm Hg) 161 6 25 160 6 26 0.81
DBP (mm Hg) 81 6 10 81 6 12 0.67
Rate–pressure product 17,700 6 4,089 17,401 6 4,654 0.57
ST segment depression
(mm)
1.4 6 0.9 1.2 6 0.7 0.01
Time (min) 5.6 6 2.6 5.7 6 2.3 0.72
*Determined by repeated measures analysis of variance, test for treatment
effect. Data are presented as mean value 6 SD. DBP 5 diastolic blood pressure;
SBP 5 systolic blood pressure; TD-NTG 5 transdermal nitroglycerin.
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use of TD-NTG compared with placebo. There was, however,
a trend for frequency of angina to decrease during patch-on
hours with TD-NTG compared with placebo (2.0 6 3.0 vs.
2.6 6 4.2 episodes, respectively, p 5 0.18). During patch-off
hours, the frequency of angina was significantly greater when
patients were using TD-NTG as compared with placebo (1.1 6
2.1 vs. 0.7 6 1.6 episodes, respectively, p 5 0.03). This
difference was related to consistent increases in the frequency
of angina associated with activity, rest and sleep during these
patch-off hours.
Analysis of AECG data for all hours (Table 4) revealed
no overall difference between TD-NTG and placebo with
respect to the frequency (0.08 6 0.13 vs. 0.09 6 0.12
episodes/h, respectively, p 5 0.55) or duration (0.64 6 1.52 vs.
0.63 6 1.01 min/h, respectively, p 5 0.94) of ischemia.
Evaluation of patch-on hours, however, revealed a trend
for frequency and duration of ischemia to decline with
TD-NTG as compared with placebo (0.07 6 0.15 vs. 0.12 6
0.19 episodes/h, respectively, p 5 0.11; 0.62 6 1.80 vs. 0.78 6
1.19 min/h, respectively, p 5 0.22). Notably, when the
TD-NTG patch was removed (patch-off), the opposite trend
was observed, with an increase in frequency and duration of
ischemia as compared with placebo (0.08 6 0.20 episodes/h vs.
0.05 6 0.09 episodes/h, respectively, p 5 0.08; 0.67 6 2.43 vs.
0.43 6 1.48 min/h). This change in frequency of ischemia from
patch-on to patch-off periods differed significantly when using
TD-NTG patches compared with placebo patches with the
mean frequency increasing by 14% during TD-NTG and
decreasing by 58% during placebo (p 5 0.01) (Fig. 1). A
similar pattern was observed for duration of ischemia from
patch-on to patch-off hours, with an increase of 8% when
using TD-NTG and a decrease of 45% during placebo (p 5
0.22).
To further examine the effects of placebo and TD-NTG
patch removal on diurnal frequency of AECG-detected isch-
emia, data were summarized at 2-h intervals (Fig. 2). The
expected early morning increase in frequency of ischemia was
observed when patients used placebo (top panel) but not when
TD-NTG (bottom panel) was used. Using 6-h periods begin-
ning at midnight, the frequency of ischemic episodes during
TD-NTG therapy was not found to vary over time, most likely
because TD-NTG suppressed the increase in ischemia that
occurs with activation after awakening, as observed with
placebo. With placebo, the difference in frequency of ischemia
in the 6-h period after midnight compared with the 7 AM to
noon period or 1 PM to 6 PM period was highly significant (p 5
0.0014). Although not shown here, duration of ischemia was
similarly affected.
Table 3. Results of Diary Analysis*
Placebo TD-NTG p Value†
Patch-on hours
Activity 2.0 6 3.6 1.4 6 2.4 0.10
Rest 0.5 6 1.0 0.4 6 0.8 0.58
Sleep 0.02 6 0.1 0.1 6 0.3 0.26
Mental stress 0.1 6 0.4 0.2 6 0.6 0.32
Subtotal 2.6 6 4.2 2.0 6 3.0 0.18
Patch-off hours
Activity 0.2 6 0.6 0.3 6 0.8 0.32
Rest 0.3 6 0.7 0.4 6 1.3 0.28
Sleep 0.2 6 0.5 0.3 6 0.7 0.13‡
Mental stress 0.1 6 0.2 0.1 6 0.2 1.00
Subtotal 0.7 6 1.6 1.1 6 2.1 0.03
All hours
Activity 2.2 6 4.1 1.7 6 2.8 0.26
Rest 0.8 6 1.5 0.9 6 1.7 0.68
Sleep 0.2 6 0.5 0.4 6 0.8 0.08‡
Mental stress 0.2 6 0.6 0.2 6 0.7 0.36
Total 3.3 6 5.2 3.2 6 4.2 0.76
*Weekly episodes of angina reported during patch-on, patch-off and all
hours. †Determined by repeated measures analysis of variance, test for treatment
effect. ‡Wilcoxon rank-sum test. TD-NTG 5 transdermal nitroglycerin.
Table 4. Results of Ambulatory Electrocardiographic Analysis*
Placebo TD-NTG p Value
Patch-on hours
Frequency (episodes/h) 0.12 6 0.19 0.07 6 0.15 0.11
Duration (min/h) 0.78 6 1.19 0.62 6 1.80 0.56
Patch-off hours
Frequency (episodes/h) 0.05 6 0.09 0.08 6 0.20 0.08
Duration (min/h) 0.43 6 1.48 0.67 6 2.43 0.33
All hours
Frequency (episodes/h) 0.09 6 0.12 0.08 6 0.13 0.55
Duration (min/h) 0.63 6 1.01 0.64 6 1.52 0.94
*Daily ischemic episodes on ambulatory electrocardiogram. Data are pre-
sented as mean value 6 SD. TD-NTG 5 transdermal nitroglycerin.
Figure 1. Frequency (top) and duration (bottom) of AECG-detected
ischemia.
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Discussion
Rebound ischemia. An increase in ischemia, either symp-
tomatic or asymptomatic, during patch-off hours could be
important in the management of patients with ischemic heart
disease. Because most ischemia is asymptomatic, it is therefore
useful to consider both subjective and objective aspects of
ischemia. In these clinically stable patients with CAD, we
observed an increase in angina frequency during patch-off
hours when patients used TD-NTG compared with placebo
(Table 3). A similar trend was noted in daily life ischemia (Fig.
1). Our patients also received other antianginal agents (beta-
blocker or calcium antagonist, or both) and had ischemia on
the ETT as well as during daily activities, and these results
were noted after 2 weeks of an optimal dose of TD-NTG.
These results are remarkably consistent with the observa-
tions of Freedman et al. (5), who studied a smaller group of
patients. These investigators also found that rebound ischemia
occurs during patch-off hours in stable patients with CAD
taking TD-NTG and a beta-blocker or calcium antagonist, or
both. Their patients were also not selected on the basis of
stable ETT times, and only 60% had ischemia on the AECG.
Similar to our observations, a trend toward increasing duration
of ischemia during patch-off hours was found in patients
receiving active TD-NTG compared with placebo (47 6 18 vs.
23 6 9 min/24 h, respectively, p 5 0.07). In addition, the
diurnal patterns of ischemia frequency observed in their TD-
NTG group compared with their placebo group were very
similar to those noted in our study. Specifically, during pla-
cebo, there was the usual diurnal variation in ischemia fre-
quency, with little apparent attenuation by patch-on and
patch-off (Fig. 2, top). During TD-NTG, however, there was a
loss of the overnight nadir and mid-day zenith, with apparently
the same ischemia frequency occurring from midnight to 6 AM
as during the other 6-hour periods (Fig. 2, bottom).
Our results and those of Freedman et al. (5) differ from
those of Parker et al. (6), who studied stable patients with
CAD, most of whom were taking a beta-blocker without
a calcium antagonist. Their patients received either placebo
or one of three doses of TD-NTG (0.2 mg/h, 0.4 mg/h or
0.8 mg/h). After 30 days, no change in angina frequency
occurred for either TD-NTG or placebo during patch-off or
patch-on periods as compared with baseline. Their analyses
differed from ours in that we directly compared patch-off and
patch-on periods. In contrast to our patients, their patients
were highly selected based on stable ETT times, and this
selection bias probably relates to the infrequent angina ob-
served while they were taking placebo (1.7 vs. 3.3 episodes/
week in our patients). These observations suggest that CAD
was functionally less severe in their patients compared with
ours, and failure to detect a difference in angina frequency
during patch-off hours may have been due to insufficient
statistical power to detect these changes.
In our study, the magnitude of ischemia during ETT
declined and a trend for angina to decrease during TD-NTG
compared with placebo was observed. We also noted a trend
suggesting an increase in ischemia when the TD-NTG patch
was removed compared with placebo patch-off hours. One
possibility to explain these observations is that TD-NTG
partially suppresses increases in ischemia and when removed,
rebound occurs. Based on our findings and those of Freedman
et al. (5), it seems likely that some patients receiving intermit-
tent TD-NTG are at risk for occurrence of an increase in
ischemia during patch-off hours.
Comparison with placebo. In this study, the effectiveness of
TD-NTG for angina was not apparent compared with placebo,
but was found effective for an objective ischemia marker and
ST segment depression during ETT. These less than expected
effects may be attributed to a relatively low dose of TD-NTG
(i.e., 0.2 and 0.4 mg/h) in the majority of cases. Angina was
noted more frequently during patch-off hours when patients
were using active TD-NTG compared with placebo. This
overall increase in angina frequency was a result of increases
associated with all types of reported activities.
A placebo response affecting angina frequency is well
documented and may confound analyses of intermittent TD-
NTG effects on ischemia during patch-off hours. Early antian-
ginal trials, which were not well designed, revealed up to a 90%
reduction in angina frequency with inactive therapies (7).
Placebo also improves other markers of ischemia such as ETT
time to angina and time to 1-mm ST segment depression (8).
In a randomized, double-blind study of atenolol versus placebo
Figure 2. Diurnal effects of placebo (top) and TD-NTG (bottom) on
frequency of AECG-detected ischemia. The frequency of ischemia
varied significantly with time only during placebo (p 5 0.0014) and not
during TD-NTG.
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in stable patients with CAD and ischemia during ETT and on
AECG, 39% had no recurrent ischemia on repeat AECG after
4 weeks of placebo (9), and this placebo response persisted for
1 year. More recently, a significant placebo effect was observed
in other studies with TD-NTG. In a well designed trial in 18
patients with stable CAD, effects of TD-NTG therapy on ETT
responses were evaluated (10). No differences were observed
in ETT time to 1-mm ST segment depression with any nitrate
regimens, and both placebo and nitrates increased ETT time to
ischemia compared with baseline. Similar results were ob-
served in 36 other patients with stable CAD in another well
designed trial (11). No difference in either ETT time to ST
segment depression or total ETT time was observed between
placebo and continuous TD-NTG or intermittent TD-NTG.
The only variable that was significantly different from placebo
was ETT time to angina when patients removed the TD-NTG
patch for 10 h.
Other possible explanations for a large placebo effect
include positive interactions with clinicians, application of the
topical patch (i.e., tactile stimulation) regardless of its con-
tents, diminished mental stress or a conditioning effect. With
the patch off, patients may be more aware of the absence of
treatment than during patch-on periods. Actual wearing of a
placebo patch may have a therapeutic effect. Unlike oral
medication, as a consequence of tactile feedback, the patient is
continually reminded of the presence of the patch even when
it contains placebo. This reminder may lead to a reduction in
anxiety and ischemia. To control for these possibilities, it may
be appropriate to randomize patients to a no-therapy group in
future trials.
The relative lack of significant effects of TD-NTG on
efficacy may also relate to absence of documented nitrate
responsiveness. Other studies reporting positive results with
intermittent TD-NTG screened patients for nitrate responsive-
ness. For example, 14 patients with stable CAD receiving a
beta-blocker and a calcium antagonist (12) sequentially re-
ceived continuous TD-NTG (0.4 mg/h), intermittent TD-NTG
and placebo. Nitrate responsiveness was defined as a prolon-
gation of ETT time by at least 1 min after SL-NTG adminis-
tration. In this study no differences in frequency of angina were
observed with either TD-NTG regimen compared with pla-
cebo, but intermittent TD-NTG increased total ETT time (440
vs. 360 s, p , 0.05). Other investigators who have observed
beneficial effects from use of intermittent TD-NTG excluded
patients who failed to respond to a variety of challenges with
SL-NTG (12–17). Although all patients in our study had a
history of nitrate responsiveness, this responsiveness was not
objectively evaluated, and this may have contributed to the
equivocal effectiveness of intermittent TD-NTG.
Many studies evaluating intermittent TD-NTG in stable
patients with CAD have failed to observe a decline in angina
frequency or SL-NTG use (5,13–19). Effects of intermittent
TD-NTG therapy on daily life ischemia detected by AECG has
also been inconsistent (6,16,17,20,21).
Furthermore, most of the patients in this study were
receiving a calcium antagonist or beta-blocker, or both. Other
investigations of TD-NTG effectiveness have also failed to
detect beneficial effects from TD-NTG when patients were
taking other antianginal therapies (6,11). In one study, the
comparative efficacy of intermittent TD-NTG and placebo was
evaluated in 206 patients with stable CAD concurrently receiv-
ing a beta-blocker. In this study, no differences in angina
frequency or SL-NTG use were observed between TD-NTG
and placebo (14). In a similar trial of 40 patients with stable
CAD receiving a beta-blocker and a calcium antagonist, use of
intermittent TD-NTG failed to prolong ETT time to angina or
1-mm ST segment compared with placebo (22). An increase in
ETT duration, however, was noted in patients receiving TD-
NTG as compared with placebo. Perhaps patients requiring
concurrent treatment with other antianginal agents have such
severe disease that no additional benefit can be derived from
addition of TD-NTG.
It is also possible that failure to detect significant differ-
ences between intermittent TD-NTG and placebo in our study
was related to divergent results comparing patch-on and
patch-off periods together with large variability. Although the
number of patients completing the trial was less than planned,
the actual power of this study to detect the expected difference
in ischemic episodes was $0.90, as anticipated. The estimated
sample size was calculated to detect a reduction of two
episodes of ischemia per week between intermittent TD-NTG
and placebo. The observed difference in frequency was 1.68 per
week, but the variability was greater than expected. It is
unlikely that enrollment of 10 more patients would have
substantially altered these results. In future studies, the direc-
tionally different effects on ischemia observed in patch-off
periods comparing active TD-NTG with placebo should be
examined in detail.
Conclusions. The results of this study suggest that the
anti-ischemic effects of intermittent TD-NTG in the low doses
used were minimal and may be limited by a rebound increase
in ischemia during patch-off hours. Furthermore, the results of
this study support the suggestion that use of intermittent
TD-NTG is associated with disruption in the normal diurnal
pattern of ischemia. Definitive investigation of this issue would
require evaluation of changes in ischemia using a variety of
patch-on/patch-off times.
Appendix
Second Transdermal Intermittent Dosing
Evaluation Study Investigators
Peter F. Cohn, MD, Lynn Burger, RN, State University of New York at Stony
Brook, New York; Stephen P. Glasser, MD, Nancy Ferzola, RN, University of
South Florida, Tampa, Florida; Harold Karpman, MD, Joe D’Amico, Cardiovas-
cular Medical Group of Southern California, Beverly Hills, California; Alan B.
Miller, MD, Mary Hudson, RN, University Medical Center, Jacksonville, Florida;
Carl J. Pepine, MD, Michele Mardis, Technician, University of Florida, Gaines-
ville, Florida; Douglas Campbell Russell, MD, Tonda Thompson, RN, Debbie
Woodson, RN, Veterans Administration Medical Center, Salem, Virginia; Udho
Thadani, MD, Diane Stroud, RN, Oklahoma University, Oklahoma City, Okla-
homa; John L. Walker, MD, Diane Martin, RN, Cardiology Research Associates,
Ormond Beach, Florida; Alan Wasserman, MD, Anna Nys, RN, George Wash-
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ington University Medical Center, Washington, D.C.; David Chinoy, MD, Cynthia
Buda, RN, Jacksonville, Florida; Robert Gibson, MD, Sharon Sayre, RN,
University of Virginia Medical Center, Charlottesville, Virginia.
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